Australia’s investment market has a track record of supporting the commercialisation of some of the most successful MedTech companies in the world and that appetite remains strong says Kyahn Williamson, Head of Investor Communication.
There are many reasons US investors consider ASX listed companies – and the falling Australian dollar and collapse in commodities is driving strong investor interest.
Investment in the biotech sector can be highly lucrative for the educated, patient investor. For the uninformed and inexperienced, biotechnology can be a potholed road.
Whether you sell widgets, gas, or a potential ten bagger drug, the value of a listed company depends on convincing people that they should own part of your business.
Taking a breath and plunging into the world of share trading can be a daunting experience.